Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
SCG Cell Therapy Pte. Ltd.
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06505551CT.gov Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Vulvar Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| scg142 (this asset) | SCG Cell Therapy Pte. Ltd. | P1/2 | CC · 45 |
| Cyclophosphamide | Christian Hinrichs | P2 | B |
| e7 tcr-t cells | Christian Hinrichs | P2 | B |
| Fludarabine | Christian Hinrichs | P2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Atezolizumab | M.D. Anderson Cancer Center | P2 | CCC |
| ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE | National Cancer Institute (NCI) | P2 | CCC |
| Fluorouracilum | Tarveda Therapeutics | P1/2 | CCC |
| Niraparib | Tarveda Therapeutics | P1/2 | CCC |
+11 more in the Vulvar Squamous Cell Carcinoma cohort
Other indications for scg142
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Papillomavirus-Related Squamous Cell Carcinoma | — | P1/2 | CCC · 48 |
| Cervical Squamous Cell Carcinoma | — | P1/2 | CCC · 48 |
| Vaginal Squamous Cell Carcinoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. scg142 in Vulvar Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/scg142-vulvar-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →